Reshape Lifesciences FY23 Sales $8.678M Miss $8.904M Estimate
Author: Benzinga Newsdesk | April 01, 2024 04:08pm
Reshape Lifesciences (NASDAQ:RSLS) reported quarterly sales of $8.678 million which missed the analyst consensus estimate of $8.904 million by 2.54 percent.